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SUMMARY  
Polyketide synthases assemble diverse natural products with numerous important 
applications. The thioester intermediates in polyketide assembly are covalently tethered to 
acyl carrier protein domains of the synthase. Several mechanisms for polyketide chain 
release are known, contributing to natural product structural diversification. Here we report 
a dual transacylation mechanism for chain release from the enacyloxin polyketide synthase, 
which assembles an antibiotic with promising activity against Acinetobacter baumannii. A 
non-elongating ketosynthase domain transfers the polyketide chain from the final acyl 
carrier protein domain of the synthase to a separate carrier protein and a nonribosomal 
peptide synthetase condensation domain condenses it with (1S, 3R, 4S)-3, 4-
dihydroxycyclohexane carboxylic acid. Molecular dissection of this process reveals that non-
elongating ketosynthase domain-mediated transacylation circumvents the inability of the 
condensation domain to recognize the acyl carrier protein domain. Several 3, 4-
dihydroxycyclohexane carboxylic acid analogues can be employed for chain release, 
suggesting a promising strategy for producing enacyloxin analogues. 
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INTRODUCTION  
Polyketides are a large and structurally diverse family of specialized metabolites with a 
wealth of applications in medicine and agriculture, such as the treatment of infectious 
diseases and cancer, the protection of crops, and animal health.1 Many industrially-
important polyketides are assembled by type I modular polyketide synthase (PKS) 
biosynthetic assembly lines.2 These remarkable molecular machines are capable of 
constructing a wide range of structurally complex carbon skeletons from acyl thioester 
building blocks via a series of condensation and modification reactions. With the exception 
of the loading module, each module in such PKSs is typically responsible for one round of 
chain elongation and minimally contains an acyl carrier protein (ACP) domain, which is post-
translationally modified via attachment of a phosphopantetheine prosthetic “arm” to a 
conserved serine residue and a ketosynthase (KS) domain, which catalyzes chain elongation.2 
Modular PKSs fall into two distinct phylogenetic groups that are typically distinguished by 
the presence or absence of acyltransferase (AT) domains in their modules. In cis-AT PKSs, 
each module contains an AT domain that is responsible for loading an (alkyl)malonyl 
extender unit onto the adjacent ACP domain, whereas in trans-AT PKSs individual modules 
lack AT domains. Instead, a single AT catalyzes the transfer of malonyl extender units from 
coenzyme A onto the ACP domains in each module of the PKS.  
Modular PKSs employ several strategies for generating structural diversity, such as the 
incorporation of a range of starter and extender units, various α- and β-carbon processing 
reactions after each round of chain extension and several distinct mechanisms for release of 
the fully-assembled polyketide chain.1 The most frequently encountered and well-studied 
chain release mechanism involves macrolactonization catalyzed by a thioesterase (TE) 
domain appended to the C-terminus of the final PKS module.3 Examples of TE domains that 
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catalyze chain release via thioester hydrolysis or macrolactamization are also known.3,4 In 
addition, several other types of catalytic domains have been reported to catalyze chain 
release. Examples include thioester reductase domains, which catalyze reductive release to 
form an aldehyde or primary alcohol,5,6 α-oxoamine synthase domains, which release the 
polyketide chain via decarboxylative condensation with the α-carbon of an amino acid,7,8  
and KS-like domains that catalyze condensation of the polyketide chain with a glyceryl-ACP 
to form a 4-hydroxymethyl-2-acyltetronic acid (Supplementary Fig. 1).9  
Enacyloxin IIa (1) is a polyketide antibiotic10,11 with clinically-relevant activity against 
Acinetobacter baumannii (MIC = 3 μg/ml),12 a problematic multidrug-resistant Gram-
negative pathogen. It selectively inhibits bacterial protein biosynthesis by binding to 
ribosomal elongation factor Tu.13-15 We recently identified the enacyloxin biosynthetic gene 
cluster in Burkholderia ambifaria AMMD and proposed a pathway for enacyloxin 
biosynthesis, involving construction of the 25-carbon acyl chain by an unusual modular PKS 
containing a mixture of cis and trans-AT subunits (Bamb_5925-5919).12 Release of the fully-
assembled polyketide chain from the final (Bamb_5919) subunit is proposed to proceed via 
an unusual dual transacylation mechanism. A non-elongating ketosynthase (KS0) domain 
appended to the C-terminus of Bamb_5919 is hypothesized to transfer the polyketide chain 
from the adjacent ACP domain to the C-terminal peptidyl carrier protein (PCP) domain of 
Bamb_5917 (Fig. 1a). Such KS0 domains lack a conserved His residue required for chain 
elongation and are commonly found in trans-AT PKSs (Supplementary Fig. 2). They are 
proposed to transfer biosynthetic intermediates between ACP domains,16, 17 but biochemical 
evidence for this is limited to a single partially characterized example,18 and their functional 
significance remains unclear. Once the fully assembled enacyloxin polyketide chain has been 
transferred to the PCP domain of Bamb_5917 it is proposed to be released via condensation 
5 
 
with the C-3 hydroxyl group of (1S, 3R, 4S)-3, 4-dihydroxycyclohexane carboxylic acid 
(DHCCA). Bamb_5915, which shows sequence similarity to condensation (C) domains, 
typically responsible for peptide bond formation between PCP-bound amino acyl thioesters 
in nonribosomal peptide synthetase (NRPS) multienzymes, is hypothesized to catalyze this 
reaction (Fig. 1a).12 
Here, we report an extensive set of genetic and biochemical experiments that establish the 
role played by Bamb_5915, Bamb_5917 and the KS0 domain of Bamb_5919 in the unusual 
chain release mechanism employed by the enacyloxin PKS. These experiments demonstrate 
that the Bamb_5919 KS0 domain overcomes the inability of Bamb_5915 to recognize the 
Bamb_5919 ACP domain by transferring the fully assembled polyketide chain to the PCP 
domain of Bamb_5917. We also show that Bamb_5915 possesses relaxed substrate 
specificity, indicating that it has the potential to be exploited for the production of novel 
enacyloxin analogues. 
 
RESULTS 
Bamb_5915 and Bamb_5917 are required for enacyloxin biosynthesis 
To establish whether Bamb_5915 and Bamb_5917 are required for enacyloxin IIa 
biosynthesis, we created in-frame deletions in the corresponding genes. Because our 
originally identified enacyloxin producer, B. ambifaria AMMD, proved refractory to genetic 
manipulation using a homing endonuclease-based mutagenesis system19, these deletions 
were created in B. ambifaria BCC0203 (also known as B. ambifaria BC-F20). The enacyloxin 
biosynthetic gene cluster in B. ambifaria BCC0203 has the same organization as that in the 
AMMD strain and shows a very high degree of sequence similarity (Supplementary Fig. 3). 
UHPLC-ESI-Q-TOF-MS analyses of extracts from agar cultures showed that enacyloxin 
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production is abolished in the bamb_5915 and bamb_5917 mutants. Complementation of 
these mutants via in trans expression of deleted genes restored enacyloxin production (Fig. 
1b). These results show that Bamb_5915 and Bamb_5917 play an essential role in enacyloxin 
biosynthesis. 
 
The Bamb_5919 KS0 domain is a carrier protein transacylase 
To investigate the function of the Bamb_5919 KS0 domain, we overproduced Bamb_5917, its 
C-terminal PCP domain (lacking the N-terminal domain of unknown function), and the ACP 
and KS0 domains of Bamb_5919 (both individually and as an ACP-KS0 di-domain) in E. coli as 
N-terminal His6-fusion proteins, and purified them to homogeneity using nickel affinity 
chromatography (Supplementary Fig. 4). The identity of all purified proteins was confirmed 
by UHPLC-ESI-Q-TOF-MS (Supplementary Fig. 4; note that Bamb_5917, and the ACP/PCP 
domains of Bamb_5919 and Bamb_5917 are produced in their apo-forms, presumably 
because the E. coli phosphopantetheinyl transferase is unable to recognize them).  
 
We first sought to establish the function of the KS0 domain, which has been hypothesized to 
catalyze the transfer of the fully assembled polyketide chain from the Bamb_5919 ACP 
domain to the Bamb_5917 PCP domain. To investigate this hypothesis, we converted the 
Bamb_5917 PCP domain to its holo-form by incubating it with CoA and the 
phosphopantetheinyl transferase Sfp (Supplementary Fig. 5). Similarly, an S-acetyl derivative 
of the holo-ACP domain from Bamb_5919 was created by incubating the apo-protein with 
Sfp and acetyl-CoA (Supplementary Fig. 6). The acetylated Bamb_5919 ACP domain was 
incubated with the Bamb_5919 KS0 domain and the Bamb5917 holo-ACP domain to examine 
whether the KS0 domain can transfer the acetyl group (which serves as a simple mimic of the 
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fully assembled enacyloxin polyketide chain) from the ACP domain to the PCP domain. 
UHPLC-ESI-Q-TOF-MS analyses of the resulting mixture showed that 40.2 ± 1.4 % of the PCP 
domain underwent acetylation (Fig. 2a). Due to the similar bond enthalpies for the linkages 
broken/formed in this reaction, an approximately 1:1 mixture of the ACP and PCP thioesters 
is produced. The level of acetylation of the Bamb_5917 PCP domain significantly decreased 
when the Bamb_5919 KS0 domain was omitted from the reaction (8.4 ± 0.9 %), or when it 
was replaced with a C1988A mutant (in which the thiol group has been removed from the 
active site Cys residue; 7.9 ± 0.8 %). These data are consistent with the hypothesis that the 
KS0 domain catalyses translocation of the fully assembled polyketide chain in enacyloxin 
biosynthesis from the Bamb_5919 ACP domain to the Bamb_5917 PCP domain. Substitution 
of the Bamb_5919 ACP and KS0 domains with the ACP-KS0 di-domain, or the Bamb_5917 PCP 
domain with full-length Bamb_5917 in these experiments gave analogous results 
(Supplementary Fig. 7 and 8). This shows that neither the covalent linkage between the ACP 
and KS0 domains, nor the N-terminal appendage of the PCP domain present in the wild type 
system are critical for catalysis of the transacylation reaction.    
To directly probe the acylation of the active site Cys residue in the Bamb_5919 KS0 domain 
during the transfer of the acetyl group from the Bamb_5919 ACP domain to the Bamb_5917 
PCP domain, the KS0 domain was incubated with a 10-fold molar excess of the acetylated 
Bamb_5919 ACP domain. Analysis of the protein mixture by UHPLC-ESI-Q-TOF-MS showed 
that the KS0 domain undergoes acetylation (35.1 ± 2.3 %) (Fig. 2b). In contrast, no 
acetylation was observed in such analyses when the acetylated Bamb_5919 ACP domain was 
incubated with the C1988A mutant of the KS0 domain. 
 
Bamb_5915 catalyzes chain release from Bamb_5917  
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The role played by Bamb_5915 (a homologue of NRPS C domains) in enacyloxin biosynthesis 
was similarly investigated via overproduction in E. coli as an N-terminal His6 fusion protein, 
purification using nickel affinity chromatography and confirmation of identity by UHPLC-ESI-
Q-TOF-MS (Supplementary Fig. 4). The S-acetyl derivative of the Bamb_5917 holo-PCP 
domain was created by incubating the apo-protein with acetyl-CoA and Sfp (Supplementary 
Fig. 6). Incubation of this simple mimic of the Bamb_5917-bound enacyloxin polyketide 
chain with Bamb_5915 and chemically synthesized racemic DHCCA resulted in the 
production of a monoacetylated DHCCA derivative, as evidenced by UHPLC-ESI-Q-TOF-MS 
analyses (Supplementary Fig. 9). The greater thermodynamic stability of the ester bond 
formed in this reaction than the thioester bond in the acetylated PCP drives product 
formation. No acetylation of DHCCA was observed when Bamb_5915 was omitted from the 
reaction.  We were unable to confirm the structure of the monoacetylated DHCCA derivative 
produced in the Bamb_5915-catalysed reaction, due to its propensity to undergo 
rearrangement during purification and the difficulty of preparing authentic standards. To 
circumvent this problem, we synthesized racemic (1S, 3R, 4S)-3-amino-4-
hydroxycyclohexane carboxylic acid (AHCCA), an analogue of DHCCA containing an amino 
group in place of the C-3 hydroxyl group. Incubation of AHCCA with the acetylated 
Bamb_5917 PCP domain and Bamb_5915 resulted in a monoacetylated product (Fig. 3a). 
The identity of this product was confirmed as N-acetyl-AHCCA by comparison with a 
chemically-synthesised standard (Fig. 3a). None of this product was formed when 
Bamb_5915 was omitted from the reaction (Fig. 3a), or when an H205A mutant of 
Bamb_5915 (in which the active site His residue known to play an important role in catalysis 
in NRPS C domains has been altered) was employed (Supplementary Fig. 10). 
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Chain transfer is necessitated by Bamb_5915 carrier protein specificity  
Having established that Bamb_5915 is able to catalyse chain release from Bamb_5917, we 
next investigated whether this enzyme can also offload acyl groups from the Bamb_5919 
ACP domain. Thus, the acetylated Bamb_5919 ACP domain was incubated with Bamb_5915 
and AHCCA. No products with an m/z corresponding to mono-acetylated AHCCA could be 
detected by UHPLC-ESI-Q-TOF-MS analysis of the reaction mixture, indicating that 
Bamb_5915 is unable to recognise acyl groups bound to the Bamb_5919 ACP domain (Fig. 
3b). These data are consistent with the ability of the Bamb_5919 KS0 domain to transfer acyl 
groups from the Bamb_5919 ACP domain to the Bamb_5917 PCP domain and strongly 
indicate that such transacylation is required to circumvent the intrinsic carrier protein 
specificity of Bamb_5915. To directly test this hypothesis, we incubated the acetylated 
Bamb_5919 ACP domain with the Bamb_5919 KS0 and Bamb_5917 holo-PCP domains, 
Bamb_5915 and AHCCA. UHPLC-ESI-Q-TOF-MS analyses confirmed that N-acetyl-AHCCA is 
produced in this reaction (Fig. 4). When the Bamb_5919 KS0 domain was omitted from the 
reaction or replaced by the C1988A mutant, small amounts of N-acetyl-AHCCA were still 
produced (Fig. 4). This likely results from uncatalyzed transfer of the acetyl group from the 
Bamb_5919 ACP domain to the Bamb_5917 PCP domain via direct transthioesterifcation, 
which has been observed in related systems.21 It is not the result of the spontaneous 
transfer of the acetyl group from the acetylated Bamb_5919 ACP domain to AHCCA, because 
no N-acetyl-AHCCA was detected when Bamb_5915 was omitted from the reaction (Fig. 4). 
Analogous results were obtained when the acetylated full length Bamb_5917 protein was 
used in place of the acetylated Bamb_5917 PCP domain (Supplementary Fig. 11). This 
indicates that the cryptic N-terminal domain of Bamb_5917 plays no specific role in the 
chain release process and is likely an evolutionary remnant. However, other roles for this 
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domain (e.g. in mediating protein-protein interactions with other components of the 
biosynthetic machinery) cannot be excluded. To provide further evidence for the relevance 
of these findings to chain release from the enacyloxin PKS, we repeated the experiments 
with acyl groups that more closely mimic the fully assembled enacyloxin polyketide chain. 
Thus, dodecanoylated and (2E, 4E)-2, 4-hexadienoylated-Bamb_5917_ACP domain were 
incubated separately with the Bamb_5919 KS0 and Bamb_5917 holo-PCP domains and 
Bamb_5915. In both cases, a monoacylated AHCCA derivative was produced 
(Supplementary Figs 12 and 13). No product could be detected when Bamb_5915 or the 
Bamb_5919 KS0 domain were omitted from reaction, or when the C1988A mutant of the KS0 
domain was used (Supplementary Figs 12 and 13). Taken together, our data show that 
Bamb_5915 is unable to interact productively with the Bamb_5919 ACP domain. This 
necessitates transfer of the fully assembled enacyloxin polyketide chain to the Bamb_5917 
PCP domain (catalysed by the Bamb_5919 KS0 domain) where it is released by Bamb_5915 
via condensation with DHCCA. 
  
Bamb_5915 tolerates various acyl acceptor and donor analogues  
The observation that Bamb_5915 can tolerate an acetyl thioester and AHCCA in place of the 
natural acyl donor and acceptor, respectively, prompted us to further investigate the 
substrate tolerance of this enzyme. To probe acyl acceptor specificity, we incubated 
Bamb_5915 with the acetylated Bamb_5917 PCP domain and several chemically-synthesized 
and commercially available DHCCA analogues. Analysis of the reaction mixtures by UHPLC-
ESI-Q-TOF-MS showed that Bamb_5915 is able to accept a variety of carbocyclic DHCCA 
analogues with variations in ring size, degree of unsaturation, substitution pattern and 
stereochemistry (Fig. 5a and Supplementary Fig. 9). Moreover, the enzyme was also able to 
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utilise acyclic DHCCA analogues, such as γ-aminobutyric acid (Fig. 5a). Indeed, the minimal 
determinant of substrate acceptance by Bamb_5915 appears to be the 1, 3-juxtaposition of 
a nucleophile and a carboxyl group (Fig. 5a and Fig. 5b). The acyl donor specificity of 
Bamb_5915 was investigated by assessing its ability to catalyse acylation of AHCCA with 
several N-acetyl cysteamine (NAC) thioester analogues of the native substrate 
(Supplementary Fig. 14). While various straight chain thioesters (e.g. acetyl, propionyl, and 
(2E, 4E)-2, 4-hexadienoyl) were well tolerated by Bamb_5915, little or no acylation of AHCCA 
was observed when the enzyme was incubated with α-branched substrates, such as 
isobutyryl, pivaloyl and serinyl-NAC thioesters.   
 
DISCUSSION 
The dual transacylation mechanism elucidated here for chain release from the enacyloxin 
modular polyketide synthase has several unusual features. First, it involves a rare 
intermolecular esterification reaction catalyzed by a standalone C domain,22 which is a novel 
mechanism for modular PKS chain release. Second, the standalone C domain appears to 
possess uncommonly broad substrate tolerance towards both acyl acceptors and acyl 
donors, and third, the polyketide chain must be translocated by a KS0 domain from a carrier 
protein domain that is not recognized by the C domain, to one that is, for chain release to 
occur.       
KS0 domains are a common feature of trans-AT PKSs,16 but their functional significance has 
remained unclear. Our data show that the KS0 domain appended to the C-terminus of 
Bamb_5919 functions as a transacylase, consistent with the hypothesis that it shuttles the 
fully assembled polyketide chain from the upstream ACP domain to the PCP domain of 
Bamb_5917. This is necessary because Bamb_5915, an NRPS-like C domain that catalyzes 
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polyketide chain release via intermolecular esterification with DHCCA, can recognize acyl 
donors when they are attached to the Bamb-5917 PCP domain, but not the Bamb_5919 ACP 
domain. Indeed, KS0 domains are commonly found at the interface between PKS and NRPS 
subunits in hybrid trans-AT PKS/NRPS assembly lines (Fig. 6),16 where they have been shown 
to play an essential role,17 and are proposed to translocate an acyl thioester intermediate 
from an upstream ACP/PCP domain to a downstream PCP/ACP domain.16 Thus, the inability 
of C (and other NRPS catalytic) domains to recognize acyl donors when they are attached to 
trans-AT PKS ACP domains appears to be a general phenomenon. Our results suggest that 
KS0 domains have been recruited during the evolution of many such hybrid systems as 
“adapters” to overcome this obstacle. In the accompanying manuscript, we show that 
protein-protein interactions mediated by mutually-compatible docking domains are 
primarily responsible for the specific recognition of the Bamb_5917 PCP domain by 
Bamb_5915.23 While it seems very likely that such interactions also underlie similar carrier 
protein incompatibilities in other systems, further experiments will be required to establish 
their precise nature.   
In the broader context, KS0 domains are frequently found juxtaposed between up- and 
downstream ACP/PCP domains in several other types of trans-AT PKS architecture.16 
Common examples include: ACP-KS0-PCP-Cy; PCP-KS0-ACP-KS; ACP-KS0-ACP-TE; ACP-KS0-
OMT-ACP; ACP-KS0-DH-ACP; and ACP-KS0-ER-ACP (domain abbreviations not defined 
previously are as follows: Cy, heterocyclisation; KR, ketoreductase; DH, dehydratase and 
related domains, including enoyl isomerases and pyran synthases; OMT, O-
methyltransferase; ER, enoyl reductase) (Fig. 6). In the all of these cases, it seems likely that 
the catalytic domains downstream of the KS0 domains cannot interact productively with the 
ACP/PCP domains upstream of them. The KS0 domains therefore transfer the acyl chains 
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attached to these ACP/PCP domains to the downstream ACP/PCP domains, which can be 
recognized by the adjacent catalytic domains, allowing the reactions they catalyze to 
proceed. Modules that recruit trans-acting oxygenases, which modify the growing polyketide 
chain during its assembly, also employ KS0 domains.16 These appear to transfer the requisite 
intermediate onto an ACP domain that can be recognized by the oxygenase. Further 
experiments will be required to test these hypotheses, but one obvious consequence is that 
in each case the ACP/PCP domain downstream of the KS0 domain must avoid being loaded 
with a malonyl extender unit by the trans-acting AT. Whether this is controlled solely by 
protein-protein interactions, as demonstrated for selective ACP recognition by the trans-AT 
KirCII in kirromycin biosynthesis,24 or more complex phenomena remains to be established. 
There is no selective pressure to maintain the HGTGT motif in a KS domain when it is 
positioned upstream of an ACP or PCP domain that cannot be malonylated. Thus KS0 
domains probably evolved from elongating KS domains via the random accumulation of 
mutations in the HGTGT motif (Supplementary Fig. 2).   
Although enacyloxin IIa has promising activity against A. baumannii,12 a multi-drug resistant 
pathogen for which new antibiotics are urgently required, it is unlikely to find direct clinical 
application. Enacyloxin analogues with enhanced potency, reduced toxicity and greater 
chemical stability are therefore needed. The broad acyl acceptor tolerance of Bamb_5915 
demonstrated by our work indicates that it may be possible to produce enacyloxin analogues 
with modifications to the DHCCA moiety via biosynthetic engineering. One attractive 
strategy for doing this involves feeding of DHCCA analogues to mutants of B. ambifaria 
blocked in DHCCA biosynthesis. Bamb_5915 is also able to accept a range of thioesters as 
acyl donors, suggesting that it may be possible to make analogues of enacyloxin with 
modifications to the polyketide chain via the manipulation of tailoring genes and other 
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biosynthetic engineering strategies. Together, such approaches offer the potential to deliver 
a library of enacyloxin analogues that illuminate the structure-activity relationship of the 
natural product, which would be an important milestone in its development towards 
therapeutic application.       
In conclusion, our results provide important insights into the mechanism and specificity of 
chain release from the enacyloxin polyketide synthase. They not only suggest a general role 
for KS0 domains in overcoming an intrinsic incompatibility between several types of catalytic 
domains and certain types of carrier protein domain in trans-AT PKSs, but also define 
plausible approaches for the production of enacyloxin analogues via biosynthetic 
engineering.  
 
METHODS 
See the Supplementary Information for a description of the methods employed. 
Data availability 
The genome sequence of B. ambifaria BCC0203 was deposited in the European Nucleotide 
Archive   (Accession No. ERS782625). All other data are available from the authors upon 
request. 
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FIGURE LEGENDS 
Fig 1: Proposed mechanism for chain release from the enacyloxin PKS and confirmation that Bamb_5915 and 
Bamb_5917 are involved in enacyloxin biosynthesis. (a) Proposed dual transacylation mechanism for chain 
release from the type I modular PKS responsible for enacyloxin IIa (1) biosynthesis. The KS0 domain at the C-
terminus of Bamb_5919 (the final PKS module) is proposed to transfer the fully-assembled polyketide chain 
from the upstream ACP domain to the Bamb_5917 PCP domain. Bamb_5915, which shows sequence similarity 
to NRPS C domains, catalyzes condensation of the resulting thioester with (1S, 3R, 4S)-3,4-
dihydroxycyclohexane carboxylic acid. (b) Deletion of the genes encoding Bamb_5915 and Bamb_5917 
abolishes enacyloxin production in B. ambifaria BCC0203. Extracted ion chromatograms at m/z = 724.2267 ± 
0.005 (corresponding to the [M+Na]+ ion for enacyloxin IIa) from UHPLC-ESI-Q-TOF-MS analyses of extracts 
from agar-grown cultures of wild type B. ambifaria BCC0203 (top), the bamb_5917 (second from top) and 
bamb_5915 (second from bottom) mutants. The chromatograms for extracts from the bamb_5915 and 
bamb_5917 mutants complemented by in trans expression of the deleted genes are also shown (bottom and 
third from bottom, respectively). The peak corresponding to enacyloxin IIa is indicated with an asterisk. The 
other peaks are isomers resulting from light / acid-promoted isomerization during isolation / analysis.  
 
Fig 2: Acyl transfer and active site acylation assays reveal that the KS0 domain of Bamb_5919 functions as a 
transacylase. (a) Deconvoluted mass spectra from incubation of the holo-Bamb_5917 PCP domain with the 
acetylated Bamb_5919 ACP domain in the presence of the Bamb_5919 KS0 domain (top) and the C1988A 
mutant of the KS0 domain (middle), and in the absence of the KS0 domain (bottom). The data demonstrate that 
the KS0 domain is able to transfer an acetyl group from the ACP domain to the PCP domain and that the active 
site Cys residue of the KS0 domain is required for this reaction. Due to the similar bond enthalpies for the 
thioester linkages broken/formed in the reaction catalyzed by the KS0 domain an approximately 1:1 mixture of 
starting material and product is formed. (b) Deconvoluted mass spectra of the Bamb_5919 ACP domain (left), 
the Bamb_5919 KS0 domain (top right) and the C1988A mutant of the Bamb_5919 KS0 domain (bottom right), 
following incubation of the wild type and mutant KS0 domains with a 10-fold excess of acetyl-Bamb_5919 ACP. 
Transfer of the acetyl group from the ACP domain to the KS0 domain is observed for the wild type enzyme 
(top), but not for the mutant in which the active site Cys residue has been mutated to Ala (bottom). The data 
shown are from a single measurement and are representative of three independent experiments. 
 
Fig. 3: Functional characterization of Bamb_5915. Extracted ion chromatograms at m/z = 224.089 ± 0.005 
(corresponding to the [M+Na]+ ion for N-acetyl-AHCCA) from UHPLC-ESI-Q-TOF-MS analyses of Bamb_5915-
calaysed reactions. (a) Incubation of the acetylated Bamb_5917 PCP domain with AHCCA and Bamb_5915 
results in a monoacetylated product with the same retention time as a chemically synthesized authentic 
standard of N-acetyl-AHCCA. (b) No acetylated products are observed when Bamb_5915 and AHCCA are 
incubated with the acetylated Bamb_5919 ACP domain. 
 
Fig. 4: In vitro reconstitution of chain release from the enacyloxin PKS. Extracted ion chromatograms at m/z = 
224.089 ± 0.005 (corresponding to the [M+Na]+ ion for N-acetyl-AHCCA) from LC-ESI-Q-TOF-MS analyses of 
synthetic N-acetyl-AHCCA (top), and the product of the reaction of the acetylated Bamb_5919 ACP domain with 
the Bamb_5915 KS0 domain, the Bamb_5917 holo-PCP domain, Bamb_5915 and AHCCA (second from top). The 
bottom three chromatograms are from control reactions in which Bamb_5915 has been omitted (third from 
bottom), the Bamb_5919 KS0 domain has been omitted (second from bottom), and the C1988A mutant of the 
Bamb_5919 KS0 domain has been used in place of the wild type enzyme (bottom). 
 
Fig. 5: Bamb_5915 tolerates a wide range of acyl acceptors. Overview of DHCCA analogues tested as 
substrates for Bamb_5915 using acetylated Bamb_5917 as an acyl donor. (a) Structures of DHCCA analogues 
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converted to monoacetylated products by Bamb_5915. (b) DHCCA analogues not accepted as substrates by 
Bamb_5915. 
Fig. 6: Examples of trans-AT PKS architectures containing KS0 domains. In each case, we hypothesize that the 
catalytic domain downstream of the KS0 domain is unable to interact with the upstream ACP/PCP domain. The 
KS0 domain thus transfers the substrate from the upstream to the downstream carrier protein domain, which 
the neighbouring catalytic domain is able to interact with, allowing the reaction it catalyses to proceed. 
Domains (other than the KS0 domain) we propose are able to engage in productive protein-protein interactions 
are shown in the same colour.      
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